z-logo
open-access-imgOpen Access
Prothrombin complex concentrates: an update.
Author(s) -
Massimo Franchini,
Giuseppe Lippi
Publication year - 2010
Publication title -
pubmed
Language(s) - English
Resource type - Journals
eISSN - 2385-2070
pISSN - 1723-2007
DOI - 10.2450/2010.0149-09
Subject(s) - prothrombin complex , fresh frozen plasma , coagulation , prothrombin complex concentrate , clotting factor , factor ix , haemophilia , coagulation disorder , medicine , haemophilia b , blood coagulation factors , vitamin k , chemistry , haemophilia a , surgery , platelet , warfarin , atrial fibrillation
Although the various coagulation factors are present at physiological concentrations in fresh-frozen plasma (FFP) derived from healthy blood donors, some virally inactivated plasma-derived coagulation factor concentrates have been available for many years. These latter products include single coagulation factor concentrates (such as factor VIII concentrates for the treatment of haemophilia A and factor IX concentrate for the treatment of haemophilia B) or the so-called prothrombin complex concentrates (PCC), which are intermediate purity pooled plasma products containing a mixture of vitamin K-dependent proteins1,2. This review will focus on the description of PCC, on their indications and safety. It will not address activated PCC for the treatment of patients with clotting factor inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom